{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiax44zxfh3cb6vgn5dek2azkkhpejecbt43zv2vzsfmzlu47weweu",
    "uri": "at://did:plc:svcthvzunxmjidtlw23zva6n/app.bsky.feed.post/3mghgyv5togt2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreigyc2daykaqse46nbobijdsxj3gmilc25g6llzqlxbvzqwp5qupk4"
    },
    "mimeType": "image/jpeg",
    "size": 35214
  },
  "path": "/2026/03/07/u-s-patient-with-advanced-lung-cancer-stabilized-by-novel-immunotherapy-treatment-in-china/",
  "publishedAt": "2026-03-07T05:12:00.000Z",
  "site": "https://laotiantimes.com",
  "tags": [
    "Cision PR Newswire"
  ],
  "textContent": "SHANGHAI, March 7, 2026 /PRNewswire/ — Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and Parkinson’s disease using ivonescimab, a novel immunotherapy currently available only in China. Dr. Xuan Linli, Chief of Medical Oncology at Jiahui International Cancer Center, stands on the patient’s right. The patient’s […]",
  "title": "U.S. Patient with Advanced Lung Cancer Stabilized by Novel Immunotherapy Treatment in China"
}